INSPIREMD INC. - COMMON STOCK

2,9500

14-февраля-25 16:45:00

15 мин. задержка

Акции

+0,0900

+3,15%

Сегодняшний диапазон

2,8000 - 2,9799

ISIN

N/A

Источник

NASDAQ

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

13 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

21 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire
InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025

12 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

09 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire
InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

25 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire
InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update

12 ноя 2024 07:00:01 Источник Nasdaq GlobeNewswire
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 ноя 2024 17:30:03 Источник Nasdaq GlobeNewswire
InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th

04 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

15 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

07 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

16 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

06 авг 2024 08:09:23 Источник Nasdaq GlobeNewswire
InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

05 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

30 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million

01 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

28 май 2024 08:53:00 Источник Nasdaq GlobeNewswire
InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

14 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

07 май 2024 07:00:01 Источник Nasdaq GlobeNewswire
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

03 апр 2024 08:59:14 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.